Canada markets close in 5 hours 37 minutes

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
23.89+0.43 (+1.83%)
As of 10:23AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close23.46
Bid23.79 x 900
Ask23.81 x 1000
Day's Range23.33 - 23.95
52 Week Range13.84 - 51.59
Avg. Volume1,283,291
Market Cap997.393M
Beta (5Y Monthly)-0.09
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec 13, 2012
1y Target EstN/A
  • GlobeNewswire

    Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates

    In Q2 2023, We Expect to Complete Patient Dosing for our Cognition Maintenance Study in Alzheimer’s disease.In Q3 2023, We Expect to Announce Results of our Cognition Maintenance Study.In Q4 2023, We Expect to Complete Patient Enrollment for our Phase 3 Studies of Simufilam in Alzheimer’s disease.Mid-year 2023, We Expect an Independent Third Party to Present Evidential Data for The Biological Activity of Simufilam Outside of Neurodegeneration.Cash And Cash Equivalents Were $201 Million at Decemb

  • GlobeNewswire

    Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease

    953 Alzheimer’s Patients Are Now Enrolled Across Phase 3 Studies Both Phase 3 Studies Have Passed the Halfway Mark for Enrollment Goal Is to Complete Enrollment for Both Phase 3 Studies by Year-End 2023 AUSTIN, Texas, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced an update on patient enrollment for its on-going Phase 3 clinical studies of simufilam for the treatment of Alzheimer’s disease dementia. Simufilam, an o

  • GlobeNewswire

    Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease

    Figure 1 Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, mild-to-moderate disease.¹ Figure 2 Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, in early disease and mild disease.² ADAS-Cog mean scores changed minimally over 1 year in patients with mild-to-moderate Alzheimer’s disease treated with open-label simufilam tablets.47% of patients improved on ADAS-Cog over 1 year, and this group improved by 4.7 point